

Tilman Schneider-Hohendorf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4175570/tilman-schneider-hohendorf-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

1,468
citations

21
h-index

38
g-index

47
ext. papers

1,844
ext. citations

7.2
avg, IF

4.11
L-index

#	Paper	IF	Citations
43	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	17
42	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1491-1496	5	3
41	Classification of neurological diseases using multi-dimensional CSF analysis. <i>Brain</i> , 2021 , 144, 2625-2634	11.2	6
40	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. <i>Brain</i> , 2021 , 144, 3126-3141	11.2	5
39	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2020 , 95, 505	6.5	0
38	MCAM/CD146 Signaling PLC β Leads to Activation of β Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. <i>Frontiers in Immunology</i> , 2020 , 11, 599936	8.4	4
37	Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2019 , 93, 550-554	6.5	11
36	Human CCR5 ^{high} effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019 , 142, 3411-3427	11.2	19
35	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	56
34	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. <i>BMC Neurology</i> , 2019 , 19, 190	3.1	8
33	VLA-2 blockade in vivo by vatelizumab induces CD4 ⁺ FoxP3 ⁺ regulatory T cells. <i>International Immunology</i> , 2019 , 31, 407-412	4.9	5
32	Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019 , 6, e627	9.1	28
31	CD8 T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019 , 10, 5779	17.4	46
30	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 271-276	11.5	28
29	Sex bias in MHC I-associated shaping of the adaptive immune system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2168-2173	11.5	28
28	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. <i>Multiple Sclerosis Journal</i> , 2019 , 24, 562-573	5	19
27	Immune Cell Profiling During Switching From Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study. <i>Frontiers in Immunology</i> , 2018 , 9, 1560	8.4	17

26	Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. <i>Journal of Neuroinflammation</i> , 2018 , 15, 236	10.1	19
25	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1871-1882	5	15
24	Nitazoxanide May Modify the Course of Progressive Multifocal Leukoencephalopathy. <i>Journal of Clinical Immunology</i> , 2018 , 38, 4-6	5.7	2
23	Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. <i>Neurology</i> , 2017 , 88, 1197-1205	6.5	79
22	Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	2
21	CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. <i>Neurology</i> , 2016 , 87, 958-9	6.5	6
20	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17
19	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e195	9.1	52
18	CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. <i>Neuro-Oncology</i> , 2016 , 18, 807-18	1	90
17	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1048-60	5	57
16	Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia. <i>JMM Case Reports</i> , 2016 , 3, e005053	0.5	6
15	CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. <i>Nature Communications</i> , 2016 , 7, 11153	17.4	64
14	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E2973-82	11.5	98
13	Therapeutic uses of anti- α -integrin (anti-VLA-4) antibodies in multiple sclerosis. <i>International Immunology</i> , 2015 , 27, 47-53	4.9	37
12	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). <i>BMC Neurology</i> , 2015 , 15, 96	3.1	5
11	Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 906-19	5.3	29
10	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. <i>Annals of Neurology</i> , 2014 , 75, 739-58	9.4	85
9	Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. <i>Aids</i> , 2014 , 28, 793-5	3.5	19

8	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1833-46	16.6	96
7	L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013 , 81, 865-71	6.5	127
6	Immunological and clinical consequences of treating a patient with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 335-44	5	35
5	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011 , 1808, 2036-44	3.8	31
4	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. <i>Journal of Autoimmunity</i> , 2011 , 36, 106-14	15.5	64
3	Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. <i>European Journal of Immunology</i> , 2010 , 40, 3581-90	6.1	47
2	Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. <i>PLoS ONE</i> , 2010 , 5, e15478	3.7	19
1	Effects on capacitance by overexpression of membrane proteins. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 369, 1022-6	3.4	59